3,3',5-triiodothyroacetic acid (Triac)

Subscribe to Selected New Research on 3,3',5-triiodothyroacetic acid

60 relevant articles (7 outcomes, 8 trials/studies) found for this Bio-Agent

Description: RN given refers to parent cpd; a metabolite of T3 and T4 thyroid hormones; promoted for hyperlipidemia, localized lipodystrophy, and obesity

Also Known As:

Triac; tiratricol; 3,3',5-triiodothyroacetic acid, sodium salt; 3,5,3'-triiodothyroacetic acid; 3,5-diiodo-3'-isopropylthyroacetic acid; DB brand of 3,3',5-triiodothyroacetic acid; Laphal brand of 3,3',5-triiodothyroacetic acid; Triacana; Téatrois; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodobenzeneacetic acid

Relationship Network

Bio-Agent Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists

Hormones: 46253

Thyroid Hormones: 2083

Thyronines: 60

Triiodothyronine: 2243

3,3',5-triiodothyroacetic acid: 60

Amino Acids, Peptides, and Proteins

Amino Acids: 8786

Cyclic Amino Acids: 2

Aromatic Amino Acids: 234

Thyroxine: 5689

Thyronines: 60

Triiodothyronine: 2243

3,3',5-triiodothyroacetic acid: 60

Experts

1.	Zeh, Alexander: 1 article (08/2008)
2.	Planert, Michael: 1 article (08/2008)
3.	Wohlrab, David: 1 article (08/2008)
4.	Klima, Stefan: 1 article (08/2008)
5.	Hein, Werner: 1 article (08/2008)
6.	Bulthuis, Gerben J: 1 article (02/2008)
7.	Nijenbanning, Gert: 1 article (02/2008)
8.	Veldhuizen, Albert G: 1 article (02/2008)
9.	Törmä, H: 1 article (08/2004)
10.	Vahlquist, A: 1 article (08/2004)

Related Diseases

1.	Goiter 10/01/1992 - "We found no significant clinical improvement with a maximal dose of Triac (2.1 mg/day), only minimal reduction in goiter size; mild decreases in T3 (9.9 to 6.7 nmol/L), free T4 (205 to 113 pmol/L), and TSH (5.7 to 5.4 mU/L); no change in STI (left ventricular ejection time, 0.389 to 0.401 sec); and an increase in O2 consumption (VO2, 164 to 209 mL/min). " 11/01/2007 - "These results show that Triac is more effective than L-T4 on goiter size, while having similar peripheral effects." 11/01/2003 - "The present results show that TRIAC is more effective than L-T(4) in the reduction of goiter size, with comparable effects on peripheral parameters." 11/01/2007 - "Goiter volume fell by at least 50% in 42% of patients treated with Triac and in 17.7% of patients treated with L-T4 (p=0.15). " 05/01/2004 - "Our results showed that TRIAC was more effective than T (3) to reduce MMI-induced goiter in a short-term goiter involution assay. " Order ALL the reference details at left...
2.	Hyperthyroidism 10/01/1997 - "We thus recommend testing the efficacy of TRIAC therapy in all RTH patients presenting with clinical features of hyperthyroidism." 06/01/2002 - "Such was the case with this patient who presented with signs, symptoms, and biochemical evidence of hyperthyroidism that promptly resolved after discontinuation of tiratricol therapy. " 06/01/2002 - "Symptomatic hyperthyroidism in a patient taking the dietary supplement tiratricol." 11/01/1989 - "3,5,3'-triiodothyroacetic acid is an effective inhibitor of TSH secretion in central hyperthyroidism. " 08/01/1989 - "We gave Triac to a woman with selective pituitary resistance for treatment of hyperthyroidism (patient 1) and to a man with generalized resistance and chronic schizophrenia to determine whether it would improve his schizophrenia (patient 2). " Order ALL the reference details at left...
3.	Body Weight (Weight, Body) 02/01/1988 - "The body weight significantly fell in both groups, without any difference between TRIAC treated and untreated patients. " 01/01/1982 - "Treatment by TRIAC decreases the body weight gain in obese rats compared with controls but it has no statistically significant effect on the relative protein turnover in either obese or lean rats." 01/01/1982 - "Genetically obese female rats (fa/fa) and their lean littermates (Fa/-) were given oral administration of 3,5,3-triiodothyroacetic acid (TRIAC) (20 micrograms/ 100 g of body weight/ day) during 4 weeks. " 12/01/1989 - "The effects of TRIAC on peripheral thyroid hormones, TSH incretion and peripheral tissue parameters were investigated in 13 mildly obese patients (group I) and 10 volunteers of normal body weight (group II). " 03/01/1989 - "When 30 micrograms triac/100 g body weight was administered, serum TSH levels remained depressed 24 h later, while pituitary mRNA content was essentially the same as in the hypothyroid controls. " Order ALL the reference details at left...
4.	Syndrome 07/01/2005 - "Long-term TRIAC therapy was effective in the management of the endocrine and neuropsychological manifestations of the syndrome. " 01/01/2004 - "This treatment was stopped because of the inconsistent response, monotherapy with tri-iodothyroacetic acid (TRIAC) was then prescribed after molecular diagnosis confirmed RTH syndrome. " 07/25/2000 - "3,5,3'-triiodothyroacetic acid (Triac) is a naturally occurring triiodothyronine (T(3)) analog, which has been used on an empirical basis to treat the syndrome of resistance to thyroid hormone (RTH). " Order ALL the reference details at left...
5.	Thyroid Hormone Resistance Syndrome (Thyroid Hormone Resistance) 08/01/1989 - "Triac has been used successfully to treat eight patients with thyroid hormone resistance. " 08/01/1989 - "3,5,3'-triiodothyroacetic acid therapy for thyroid hormone resistance." Order ALL the reference details at left...

Related Drugs and Biologics

1.	3,3',5-triiodothyroacetic acid (Triac)
2.	Hormones
3.	Thyroxine (Levothyroxine)
4.	Thyrotropin (Thyroid-Stimulating Hormone)
5.	Triiodothyronine (Liothyronine)
6.	Propranolol (Inderal)
7.	Thyroid Hormones
8.	tetraiodothyroacetic acid (TA(4))
9.	Verapamil (Calan)
10.	Thyrotropin-Releasing Hormone (Prolactin Releasing Hormone)

Related Therapies and Procedures

1.	Braces
2.	Orthotic Devices (Orthosis)
3.	Oral Administration
4.	Therapeutic Abortion

Best Treatments:
Research Summary Report
on Goiter

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 82 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>